



# German CDISC UG Meeting

Ingelheim, 05. September 2017

Introduction to Boehringer Ingelheim

# Introduction

**Andrea Rauch**

Global Head of Clinical  
Data Standards

# Boehringer Ingelheim in brief



## Boehringer Ingelheim Center

Our headquarter  
in Ingelheim

- Family-owned global corporation
- Founded 1885 in Ingelheim, Germany
- Focus on Human pharmaceuticals, Animal health and biopharmaceutical contract manufacturing
- Around 45,700 employees worldwide
- Four R&D sites worldwide
- R&D expenditure of EUR 3.1 billion
- 17 production facilities (human pharmaceuticals) in 11 countries
- Net sales of around EUR 15.9 billion
- 143 affiliated companies worldwide
- Investment in tangible assets: EUR 645 million

Status: 31.12.2016


# Global Research and Development presence



- Global research and development presence in Europe, North America and Asia
- Industry-leading expertise in research, development and medicine
- Extensive capabilities in both small molecule drugs and biotherapeutics
- Actively extending our global community of innovation partners
- *Research Beyond Borders* capturing emerging science for and beyond our core therapeutic areas



# Research and Development Innovation: Four focus areas





# BDS Organisational Structure

